Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a report on Monday, March 10th. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Up 0.9 %

TENX opened at $6.55 on Friday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.89. The company has a market cap of $26.00 million, a price-to-earnings ratio of -1.23 and a beta of 2.20. The firm’s fifty day simple moving average is $6.44 and its two-hundred day simple moving average is $5.46.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.34. On average, research analysts forecast that Tenax Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Tenax Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC purchased a new stake in shares of Tenax Therapeutics during the 4th quarter worth approximately $1,026,000. Sphera Funds Management LTD. acquired a new stake in Tenax Therapeutics in the third quarter valued at about $101,000. Millennium Management LLC purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at approximately $166,000. Geode Capital Management LLC boosted its position in shares of Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Tenax Therapeutics during the 4th quarter worth $84,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.